New study with funding from the NIA to look at compounds other than SIRT501.....
(note, I copied and pasted only part of the article with the more scientifically relevant parts-I cut out Westphal and Sinclair's self serving comments
on how great this new study would be.)
National Institute of Aging Funding to Study the Beneficial Effects of SIRT1 Activation on Diseases of Aging
Thursday September 6, 8:00 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals (NASDAQ: SIRT - News), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Institute of Aging (NIA). Sirtris and its academic collaborators were awarded funding to study the effects of one of its new chemical entities (NCEs) on diseases of aging in mice. The NCE, which is structurally distinct from, and significantly more potent than Sirtris' proprietary resveratrol product (SRT501), will be tested in aging mice.
(cut out 2 paragraphs here)
About New Chemical Entities (NCEs)
New chemical entities which activate SIRT1 are structurally unrelated to and significantly more potent than SRT501, an improved formulation of resveratrol. SIRT1 is a member of the human sirtuin family of enzymes. Specifically, NCEs act by increasing mitochondrial activity in pre-clinical models of disease, and we believe they may be therapeutic for metabolic diseases like Type 2 Diabetes as well as other diseases of aging such as neurological and inflammatory disorders, and cancer.
About Sirtuins
Sirtuins are a recently-discovered family of enzymes that appear to regulate certain beneficial effects of calorie restriction. There are seven human sirtuins (SIRT1-7), each having a different sub-cellular localization. Sirtris believes that sirtuins are attractive drug targets since some have a specialized function in mitochondrial activity which may be therapeutically beneficial for metabolic and other diseases. By harnessing a natural process, Sirtris believes sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.
